Anti-fibrotic compounds and use thereof

A method of treating or inhibiting pulmonary fibrosis in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula X, or salts, hydrates, solvates, polymorphs, optical isomers, geometrical isomers, enantiomers, diastereomers, or mixtures thereof:

• wherein L is a linker selected from the group consisting of:
• C1-C10 alkylene, C2-C10 alkenylene, and C2-C10 alkynylene, and
• Ar is selected from the group consisting of:
• phenyl substituted with at least one of methyl, methoxy, amido, amino, and nitro;
• C10-C18 fused bicyclic aryl optionally substituted with at least one of hydroxy, amido, alkylamido, amino, alkylamino, carboxyl, CH2CH2OH, and CH2CH2OCH2CH2OH;
• and
• C5-C9 fused bicyclic heteroaryl optionally substituted with at least one of hydroxy, amido, alkylamido, amino, alkylamino, carboxyl, C1-C4 alkyl, C1-C4 alkoxy, halogen, haloalkyl, nitro, cyano, CH2CH2OH, and CH2CH2OCH2CH2OH, provided that when Ar is C5-C9 fused bicyclic heteroaryl substituted with methoxy and amino, then the amino is not an aniline group.